Evidence map›Paper›PMID 36852359›Full record

ArticleCureus2023

Magnetic Resonance Imaging Scan of the Brain After Mild COVID-19 Infection.

Makoto Ohtake, Jun Suenaga, Taisuke Akimoto, Hisataro Ikeuchi, Ayumu Muroya, Hiroyuki Ohata, Yoshihiro Kubota, Masaaki Chiku, Tomoaki Hamano, Tetsuya Yamamoto

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Makoto OhtakeDepartment of Neurosurgery, Yokohama City University Hospital, Yokohama, JPN.
Jun SuenagaDepartment of Neurosurgery, Yokohama City University Hospital, Yokohama, JPN.
Taisuke AkimotoDepartment of Neurosurgery, Yokohama City University Hospital, Yokohama, JPN.
Hisataro IkeuchiDepartment of Smart Brain Screening, Smartscan, Inc., Tokyo, JPN.
Ayumu MuroyaDepartment of Smart Brain Screening, Smartscan, Inc., Tokyo, JPN.
Hiroyuki OhataDepartment of Smart Brain Screening, Smartscan, Inc., Tokyo, JPN.
Yoshihiro KubotaDepartment of Neurosurgery, Medical Check Studio, Tokyo, JPN.
Masaaki ChikuDepartment of Neurosurgery, Medical Check Studio, Tokyo, JPN.
Tomoaki HamanoDepartment of Smart Brain Screening, Smartscan, Inc., Tokyo, JPN.
Tetsuya YamamotoDepartment of Neurosurgery, Yokohama City University Hospital, Yokohama, JPN.
Start Making A Reader Today · USYokohama City University Hospital · JPCheck Point (Israel) · ILYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere have been several reports of central nervous system impairments associated with severe coronavirus disease 2019 (COVID-19) infection on head magnetic resonance imaging and angiography (MRI/A). However, head MRI/A is rarely performed in mild cases, and there have been few reports on intracranial changes after COVID-19 infection in these cases. Here, we report a comparative examination of the findings seen in common head MRI/A sequences in mild cases of COVID-19.

methodsOf the 15,376 patients who underwent head MRI/A examination called "Brain Dock" between June 2020 and June 2021, 746 patients who received a COVID-19 antibody test were evaluated. Positive and negative patients were comparatively examined for head MRI/A findings such as cerebral white matter lesions, ischemic changes, cerebral microbleeds, cerebral aneurysms, arterial stenosis, sinusitis, and other abnormal findings.

resultsOverall, 31 (4.2%) patients were COVID-19 positive, and all of them had mild infections not requiring hospitalization. There was no significant difference in patient characteristics and head MRI/A findings between positive and negative patients. All positive patients showed no particular abnormalities in the nasal findings such as olfactory bulb atrophy or thickening of the olfactory mucosa.

conclusionIntracranial lesions in mild patients do not show a clear difference from those in negative patients. This indicates that findings seen in common MRI/A sequences of severe patients are not likely in mild patients, supporting that there is relatively no damage to the central nervous system in mild patients.

Indexed as

brain screeningcovid-19 antibody testmagnetic resonance angiography (mra)magnetic resonance imaging ( mri)mild covid-19 infection

Identifiers

PMID36852359
PMCPMC9963390
OpenAlexW4318070719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.